POSITION STATEMENTS
For Healthcare Professionals
January 23, 2013
Calcium Supplements and Risk of Heart Disease
Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada Calcium is essential for the achievement and maintenance of normal bone health. The current daily requirements for […]
November 27, 2012
Prolia and Atypical Fractures
An atypical femoral fracture is an uncommon type of hip fracture which has been associated with long term use of certain osteoporosis medications. This type of hip fracture affects the […]
June 27, 2012
Bisphosphonates and atypical fractures
We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]
April 11, 2012
New Study Confirms that Potential Side Effect of Bisphosphonate Therapy on the Eyes is Very Rare
A recently released Canadian research study confirms what has been shown in past preliminary studies; – inflammation of the eye as a possible side effect of bisphosphonate therapy is very […]
August 27, 2010
Osteoporosis Canada Statement on Esophageal Cancer and Bisphosphonate Use
No link between the use of bisphosphonates and the risk of cancer of the esophagus or stomach has also been noted in a recent large study from the UK. This […]
May 27, 2010
High-Dose Oral Vitamin D and Falls and Fractures
A recent study, Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women, published in the Journal of the American Medical Association (JAMA), showed that a single large […]
July 14, 2009
The reported association between use of zoledronic acid (Aclasta) and renal impairment
We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]
November 27, 2008
Fosamax and atrial fibrillation: Osteoporosis Canada responds
We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]
January 22, 2008
Osteonecrosis & Bisphosphonate position statement
Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada • Dr. Rick Adachi, Rheumatologist, McMaster University • Dr. Robert Josse, Endocrinologist, University of Toronto • Dr. […]